DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness

Information source: Korea University Anam Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 2; Metabolic Syndrome X

Intervention: cilostazol (Drug); Placebo (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Korea University Anam Hospital

Official(s) and/or principal investigator(s):
Sin Gon Kim, MD, PhD, Principal Investigator, Affiliation: Korea University Anam Hospital

Overall contact:
Hee Young Kim, MD, PhD, Phone: +82-2-920-5767, Email: lynsette@korea.ac.kr


Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication. Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and inhibitor of platelet aggregation. Recently there were report of beneficial effect of cilostazol like vasodilation, lipid metabolism, and cytokine production. But there were few clinical studies that support these effects of cilostazol. The purpose of this study is to evaluate the vasodilatory and anti-inflammatory effect of cilostazol presented by PWV and plasma adipocytokines.

Clinical Details

Official title: Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The effect on pulse wave velocity (PWV)

Secondary outcome: the effect on atherosclerotic and inflammatory markers such as adiponectin, hsCRP


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


- Eligible for study: 18 year and above, Gender eligible for study: both Inclusion

Criteria: Type 2 diabetes patients with metabolic syndrome criteria of Asian-Pacific ATP III guideline

- Type 2 diabetes (at least 1 criteria below)

1. fasting blood glucose ≥ 126 mg/dL 2. postprandial 2hour glucose ≥ 200 mg/dL 3. random blood glucose ≥ 200 mg/dL with typical diabetes symptoms

- Metabolic syndrome : Asian-Pacific ATP III guideline

1. Fasting blood glucose ≥ 110 mg/dL, or previously diagnosed type 2 diabetes 2. systolic and/or diastolic blood pressure ≥130/85 mmHg, or treatment of previously diagnosed hypertension 3. Triglyceride ≥ 150 mg/dL, or Specific treatment for this lipid abnormality 4. HDL-cholesterol < 40 mg/dL for men and < 50 mg/dL for women, or Specific treatment for this lipid abnormality 5. Waist circumference ≥ 90 for men and ≥ 80 for women Exclusion Criteria:

- Hypertensive patients with the use of ACE inhibitor or ARB

- Hyperlipidemic patients with the use of statin or fenofibrate

- Hepatic dysfunction

- Chronic alcohol or drug abuse

- Renal dysfunction

- Heart failure

- Patients who takes hormone replace therapy or steroid containing drugs

- Patients who take drugs like anticoagulant (warfarin), anti-platelet agent (aspirin,

ticlopidin), thrombolytic agent (urikinase, alteplase), prostaglandine E1 , drugs inhibit CYP3A4 or CYP2C19, or drugs become substrate of CYP3A4

- Patients who haves disease influencing the results of the study such as neurologic,

digestive and neoplastic disease

Locations and Contacts

Hee Young Kim, MD, PhD, Phone: +82-2-920-5767, Email: lynsette@korea.ac.kr

Korea Univerisity Anam Hospital, Seoul 136-705, Korea, Republic of; Recruiting
Dong Kim, Phone: +82-2-920-6566, Email: ctcan@kumc.or.kr
Additional Information

Starting date: December 2007
Last updated: December 13, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017